Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2002-11-27
2009-08-18
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S143100, C530S351000, C530S388220
Reexamination Certificate
active
07575742
ABSTRACT:
Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5674494 (1997-10-01), Strom
patent: 5886152 (1999-03-01), Nakatani et al.
patent: 6096728 (2000-08-01), Collins et al.
patent: 2188941 (1987-10-01), None
patent: WO 89/09622 (1989-10-01), None
patent: WO 90/07861 (1990-07-01), None
patent: 93/01289 (1993-01-01), None
patent: WO 98/13067 (1998-04-01), None
patent: 00/25816 (2000-05-01), None
patent: 2004/003156 (2004-01-01), None
Goldsby RA, et al. Kuby, Immunology. 4th Ed. 2000. W.H. Freeman and Company. New York, NY. p. 497-503.
Jacobs LD, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology. 1996. vol. 39(3), p. 285-294.
Vincenti F, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. New Eng. J. Med. 1998. vol. 338, p. 161-165.
Hayosh N.S. et al. IX. Inhibition of adoptive transfer or autoimmune encephalomyelitis with a monoclonal antibody specific for interleukin 2 receptors. J. Immunol. 1987. vol. 138, p. 3771-3775.
Bellamy et al., “The Distribution of Interleukin-2 Receptor Bearing Lymphocytes in Multiple Sclerosis: Evidence for a Key Role of Activated Lymphocytes,”Clin. Exp. Immunol., 61:248-256 (1985).
Giorelli et al., “IFN-beta1a Modulates the Expression of CTLA-4 and CD28 Splices in Human Mononuclear Cells: Induction of Soluble Isoforms,”J. Interferon Cytokine Res., 21:809-12 (2001).
“Industry News (Transplantation): FDA Approval of Zenapax for Kidney Transplants Announced,”Cancer Weekly, p. 2 (1997).
Junghans et al., “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders,”Cancer Res., 50:1495-1502 (1990), abstract only.
Khoury et al., “Changes in Activated T Cells in the Blood Correlate with Disease Activity in Multiple Sclerosis,”Arch Neurol, 57:1183-1189 (2000).
Lehky et al., “Reduction in HTLV-I Proviral Load and Spontaneous Lymphoproliferation in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis Patients Treated with Humanized Anti-Tac,”Ann. Neurol., 44:942-947 (1998).
Marwick, “Scientists Recall Progress and Promise of Translational Research,”J. Natl. Cancer Inst., 93:13-15 (2001).
Nussenblatt et al., “Treatment of Noninfectious Intermediate and Posterior Uveitis with the Humanized Anti-Tac mAb: A Phase I/II Clinical Trial,”Proc. Natl. Acad. Sci., 96:7462-7466 (1999).
Paty et al., “Interferon beta-1b is effective in relapsing—remitting multiple sclerosis,”Neurology43:662-667, 1993.
Posey et al., “New Drugs for 1997,” www.ascp.com/public/pubs/tcp/1997/apr
ewdrugs, 21pp. (1997).
“Study of Zenapax in the Treatment of Multiple Sclerosis,” www.mult-sclerosis.org
ews/Nov2000/ZenapaxMS, 4pp. (Nov. 2000).
Wandinger et al., “Complex Immunomodulatory Effects of Interferon-beta in Multiple Sclerosis Include the Upregulation of T Helper 1-associated Marker Genes,”Ann. Neurol., 50(3):349-57 (2001).
Becker et al. “Differential Gene Expression in Multiple Sclerosis Lesions Identified Using cDNA Microarrays,”Poster Abstracts / J. Neuroimmunology90:71 (1998) Abstract only.
Sharief et al. “Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-β therapy,”J. Neuroimmunology129:224-231 (2002).
Queen et al, “A humanized antibody that binds to the interleukin 2 receptor,”Proceedings of the National Academy of Sciences of the USA, 86(24):10029-10033 (Dec. 1989).
L'Episcopo et al., “Natural interferon-β treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study,”ACTA Nuerologica Scandinavica100:283-289 (Nov. 1999).
Bielekova Bibiana
Martin Roland
McFarland Henry
Waldmann Thomas
Hissong Bruce D.
Klarquist & Sparkman, LLP
Landsman Robert
The United States of America as represented by the Secretary of
LandOfFree
Method of treating autoimmune diseases with interferon-beta... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating autoimmune diseases with interferon-beta..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating autoimmune diseases with interferon-beta... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110190